133 related articles for article (PubMed ID: 37952281)
41. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
42. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
43. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
44. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
45. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
46. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
[TBL] [Abstract][Full Text] [Related]
47. Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Lindberg Å; Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbaek K; Geisler CH; Jerkeman M
Hematol Oncol; 2022 Feb; 40(1):22-30. PubMed ID: 34713465
[TBL] [Abstract][Full Text] [Related]
48. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW; Edwin N; Redd R; Bsat J; Chase M; LaCasce A; Freedman A; Jacobson C; Fisher D; Ng S; Crombie J; Kim A; Odejide O; Davids MS; Brown JR; Jacene H; Cashen A; Bartlett NL; Mehta-Shah N; Ghobadi A; Kahl B; Joyce R; Armand P; Jacobsen E
Blood Adv; 2020 Mar; 4(5):858-867. PubMed ID: 32126141
[TBL] [Abstract][Full Text] [Related]
49. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
50. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
51. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
52. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P; Fronkova E; Belada D; Forsterova K; Pytlik R; Kalinova M; Simkovic M; Salek D; Mocikova H; Prochazka V; Blahovcova P; Janikova A; Markova J; Obr A; Berkova A; Kubinyi J; Vaskova M; Mejstrikova E; Campr V; Jaksa R; Kodet R; Michalova K; Trka J; Trneny M
Hematol Oncol; 2018 Feb; 36(1):110-115. PubMed ID: 29083050
[TBL] [Abstract][Full Text] [Related]
53. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
[TBL] [Abstract][Full Text] [Related]
54. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
56. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
[TBL] [Abstract][Full Text] [Related]
57. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Costes-Tertrais D; Hueso T; Gastinne T; Thieblemont C; Oberic L; Bouabdallah K; Garciaz S; Tchernonog E; Dartigeas C; Ribrag V; Fogarty P; Casasnovas RO; Houot R; Delette C; Malak S; Fornecker LM; Gressin R; Damaj G; Le Gouill S
Bone Marrow Transplant; 2022 Apr; 57(4):627-632. PubMed ID: 35149851
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials.
Jing C; Zhao A; Wang J; Niu T
Cancer Med; 2023 Jul; 12(14):15107-15116. PubMed ID: 37264757
[TBL] [Abstract][Full Text] [Related]
59. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Kotchetkov R; Drennan IR; Susman D; DiMaria E; Gerard L; Nay D; Prica A
Int J Cancer; 2023 May; 152(9):1884-1893. PubMed ID: 36545885
[TBL] [Abstract][Full Text] [Related]
60. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
